Takeda Pharmaceutical Company Ltd
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Survey of Icatibant in Pediatric Participants with Hereditary Angioedema
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 32
- Registration Number
- NCT05509569
- Locations
- 🇯🇴
Takeda selected site, Tokyo, Jordan
A Study of People With CD30 Positive Lymphoma in China
- Conditions
- Lymphoma
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1006
- Registration Number
- NCT05506774
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
- Conditions
- Mucopolysaccharidosis (MPS)Hunter Syndrome
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 5
- Registration Number
- NCT05494593
- Locations
- 🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸Rady Childrens Hospital San Diego - PIN, San Diego, California, United States
A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Other: No Intervention
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 85
- Registration Number
- NCT05489640
- Locations
- 🇬🇧
Sciensus, London, United Kingdom
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 8
- Registration Number
- NCT05481437
- Locations
- 🇯🇵
Takeda selected site, Tokyo, Japan
A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- Other: PlaceboBiological: Purified Inactivated Zika Virus Vaccine (PIZV)
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Takeda
- Registration Number
- NCT05469802
- Locations
- 🇺🇸
CenExel Research Centers of America, Oakland Park, Florida, United States
🇺🇸AMR East Wichita, Formerly Heartland Associates East Wichita, an AMR company, Wichita, Kansas, United States
🇺🇸AMR Lexington, Formerly Central Kentucky Research Associates, an AMR company, Lexington, Kentucky, United States
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Other: No Intervention
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 50
- Registration Number
- NCT05469789
- Locations
- 🇬🇧
Barts Health NHS Trust, London, England, United Kingdom
A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema
- Conditions
- Alpha1-Antitrypsin DeficiencyChronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Biological: RYMPHYSIABiological: Another Available A1PI
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Takeda
- Registration Number
- NCT05466747
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT05460325
- Locations
- 🇨🇳
Yantai Yuhuangding Hospital, Yantai, Shandong, China
🇨🇳Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China
🇨🇳The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Conditions
- Crohn's DiseaseUlcerative Colitis
- Interventions
- Other: No Intervention
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 240
- Registration Number
- NCT05442567
- Locations
- 🇦🇺
Children's Hospital at Westmead, Westmead, New South Wales, Australia
🇺🇸Goryeb Children's Hospital, Morristown, New Jersey, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States